cafusertib
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2014 (NCT02140606)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine/threonine-protein kinase PLK1INHIBITOR
PLK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cafusertib hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02314884 | Phase 1 | Nov 1, 2014 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT02140606 | Phase 1 | May 1, 2014 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 2 | 2 | 1 | 2014 |
1 organizations
Page 1 / 1